Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Briacell Therapeutics Corp (BCT.TO)

Briacell Therapeutics Corp (BCT.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Briacell Therapeutics Corp 235-15th Street Suite 300, 3rd Floor, Bellevue Centre Vancouver BC V7T 2X1 CAN

https://www.briacell.com P: 888-485-6340 F: 424-245-3719

Description:

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Key Statistics

Overview:

Market Capitalization, $K 32,565
Shares Outstanding, K 36,183
Annual Sales, $ 0 K
Annual Net Income, $ -4,791 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,214 K
60-Month Beta 2.05
% of Institutional Shareholders 0.02%

Growth:

1-Year Return -83.67%
3-Year Return -93.23%
5-Year Return -92.50%
5-Year Revenue Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.07 on 10/28/22
Next Earnings Date 12/12/24
Earnings Per Share ttm -0.29
EPS Growth vs. Prev Year -10.69%
Dividend Payout Ratio 0.00%
Most Recent Split 1-300 on 01/02/20

BCT.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % -29.01%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book N/A
Book Value/Share -0.09
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar